Treatment of hemangiomatosis with recombinant interferon alfa.

Abstract:

:Hemangiomas and lymphangiomas are two main types of angiomatous disease that occur most commonly in infancy and childhood. Most hemangiomas resolve spontaneously, but some endanger vital structures such as the lung, as in pulmonary hemangiomatosis, a rare and universally fatal disease. Occasionally, hemangiomatous lesions are associated with thrombocytopenia, consumptive coagulopathy (Kasabach-Merritt syndrome), and microangiopathic hemolytic anemia. In the past, treatment of hemangiomatosis has included corticosteroids, cytotoxic drugs, laser therapy, embolization or other surgical approaches, radiation therapy, cryotherapy, and supportive measures such as the administration of platelets or clotting factors. Recently, it has been found that recombinant interferon alfa is effective in treating pulmonary hemangiomatosis, as well as other variants of hemangiomatous disease such as hemangioendotheliomas. Possible mechanisms of action for interferon include inhibiting proliferation of endothelial cells, smooth muscle cells, or fibroblasts that have been stimulated by endothelial cell or fibroblast growth factors; enhancing the production of endothelial prostacyclin; or decreasing the production of collagen. It is also possible that interferon alfa antagonizes angiogenesis indirectly through its immunostimulatory actions. With the exception of significant hemodynamic changes in some patients during the first 48 to 72 hours of therapy with interferon, side effects are relatively mild.

journal_name

Semin Hematol

journal_title

Seminars in hematology

authors

White CW

subject

Has Abstract

pub_date

1990-07-01 00:00:00

pages

15-22

issue

3 Suppl 4

eissn

0037-1963

issn

1532-8686

journal_volume

27

pub_type

杂志文章,评审
  • Structural and functional characterization of B-domain deleted recombinant factor VIII.

    abstract::A new high-purity recombinant factor VIII preparation has been developed for the treatment of hemophilia A. Structurally, this factor VIII preparation, B-domain deleted recombinant factor VIII (BDDrFVIII), differs from other recombinant and plasma-derived factor VIII preparations in that most of the B-domain has been ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90103-9

    authors: Sandberg H,Almstedt A,Brandt J,Castro VM,Gray E,Holmquist L,Lewin M,Oswaldsson U,Mikaelsson M,Jankowski MA,Bond M,Scoble HA

    更新日期:2001-04-01 00:00:00

  • Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.

    abstract::Myelodysplastic syndrome (MDS) with deletion 5q (del(5q)) is a distinct clinical and pathological disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion-dependent anemia. Although lenalidomide has erythropoeitic promoting activity in MDS without del(5q) (non-del(5q...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2017.06.003

    authors: Talati C,Sallman D,List A

    更新日期:2017-07-01 00:00:00

  • Quality of life, social challenges, and psychosocial support for long-term survivors after allogeneic hematopoietic stem-cell transplantation.

    abstract::Over the last two decades quality of life (QoL) and the social challenges of allogeneic hematopoietic stem cell transplant (allo-HSCT) survivors have been emerging as subjects of extensive research and are now considered as very important aspects in the pretransplant evaluation and management of allo-HSCT recipients. ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2011.10.004

    authors: Norkin M,Hsu JW,Wingard JR

    更新日期:2012-01-01 00:00:00

  • Monoclonal antibodies in lymphoma: the first decade.

    abstract::The past decade has seen improvements in overall survival (OS) for patients with the two most common lymphoma histologies: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). In FL, at least four independent datasets have confirmed these survival improvements. The monoclonal antibody rituximab has sign...

    journal_title:Seminars in hematology

    pub_type:

    doi:10.1053/j.seminhematol.2008.02.005

    authors: Link BK,Friedberg JW

    更新日期:2008-04-01 00:00:00

  • Which Acute Myeloid Leukemia Patients Should Be Offered Transplantation?

    abstract::Acute myeloid leukemia (AML) is a heterogeneous disease characterized by multiple genetic and epigenetic alterations. The major causes of treatment failure remain disease relapse and treatment toxicity. However, major advances in biological determinants of disease relapse, development of targeted molecules, improvemen...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2015.03.001

    authors: Brissot E,Mohty M

    更新日期:2015-07-01 00:00:00

  • Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.

    abstract::Hodgkin Lymphoma (HL) is a lymphoproliferative disorder of B cells that commonly has a favorable prognosis when treated with either combination chemotherapy and radiation therapy, or chemotherapy alone. However, the prognosis for patients who relapse, or have evidence for refractory disease, is poor and new treatments...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2016.05.011

    authors: Younes A,Ansell SM

    更新日期:2016-07-01 00:00:00

  • Perspectives on the future of chronic myeloid leukemia treatment.

    abstract::Chronic myeloid leukemia (CML) is probably the best understood human malignancy at the molecular level, but among the hardest to explain to patients concerning appropriate treatment options. At present, we do not know the long-term outcome of promising new therapies such as the tyrosine kinase inhibitor imatinib mesyl...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90116-7

    authors: Appelbaum FR

    更新日期:2001-07-01 00:00:00

  • New therapeutic strategies in acute lymphoblastic leukemia.

    abstract::While cure rates of over 80% are achieved in contemporary pediatric acute lymphoblastic leukemia (ALL) protocols, most adults with ALL succumb to their disease, and little progress has been made in the treatment of refractory and relapsed ALL. Moreover, the burden of therapy is high in a significant number of newly di...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2008.09.009

    authors: Jeha S

    更新日期:2009-01-01 00:00:00

  • Perspectives on familial chronic lymphocytic leukemia: genes and the environment.

    abstract::Chronic lymphocytic leukemia (CLL) comprises a substantial proportion of leukemias in adults in the western hemisphere. Male gender, increasing age, ethnicity (high in Caucasians, lowest in Asians), and family history are risk factors. Although no specific extrinsic etiologic factors have been established, farming and...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2004.05.002

    authors: Caporaso N,Marti GE,Goldin L

    更新日期:2004-07-01 00:00:00

  • Surface and cytoskeletal events regulating leukocyte membrane topography.

    abstract::The experiments reviewed here establish that surface components and surface functions can assume predictable, asymmetric patterns within the continuous plasma membranes of mammalian leukocytes. Recent biophysical and morphological studies show that receptor redistribution can occur very rapidly and that a unique geome...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Oliver JM,Berlin RD

    更新日期:1983-10-01 00:00:00

  • Treatment strategies for Hodgkin's disease.

    abstract::Over the past 2 decades, treatment of Hodgkin's disease has evolved considerably through innovations in the management of various stages. The impact of various treatments on the 5-, 10-, and 15-year results is being balanced against delayed morbidity, such as organ damage and second malignancies, produced by the inten...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Bonadonna G,Santoro A,Viviani S,Valagussa P

    更新日期:1988-04-01 00:00:00

  • Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia.

    abstract::Bone marrow transplantation (BMT) from a human leukocyte antigen (HLA)-matched sibling is the treatment of choice in children and young adults with severe aplastic anemia (SAA). However, because only 30% of patients have a suitable donor, more aggressive nontransplant immunosuppressive regimens have been used, with re...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90029-5

    authors: Margolis DA,Casper JT

    更新日期:2000-01-01 00:00:00

  • Surgery in hemophilia. The general view: patient selection, timing, and preoperative assessment.

    abstract::Although often overlooked, the life of the patient with severe hemophilia is characterized by both intermittent and chronic pain. Bleeds into joints and muscles cause extensive pressure on sensory nerves and, following recurrent bleeds, joint destruction, and synovial reaction is accompanied by constant pains that are...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.11.024

    authors: Ingerslev J,Hvid I

    更新日期:2006-01-01 00:00:00

  • Future strategies toward the cure of indolent B-cell malignancies. Immune recognition and antiself.

    abstract::Tumor cells from patients with B-cell malignancies exhibit a number of immunophenotypic characteristics that may be responsible for their survival. It has been shown, for example, that down-modulation of CD154 (CD40 ligand), which allows B cells to respond to T cells, may account for some of the immune defects of thes...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Nadler LM

    更新日期:1999-10-01 00:00:00

  • Management of cancer-related anemia: epoetin alfa and quality of life.

    abstract::Anemia is frequent and significantly adds to the morbidity of cancer patients, and has been associated with decreased quality of life (QOL). Three open-label community-based studies of epoetin alfa in cancer-related anemia (two using three-times-weekly dosing and one using once-weekly dosing) in more than 7,000 patien...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90062-3

    authors: Soignet S

    更新日期:2000-10-01 00:00:00

  • Activity survey and historical perspective of autologous stem cell transplantation in Europe.

    abstract::Autologous hematopoietic stem cell transplantation (HSCT) has a long tradition in Europe. Initially developed as a tool to restore rapid remission or chronic phase in patients with advanced leukemia without a sibling donor, it evolved over the last three decades to be used as a standard tool in patients with malignanc...

    journal_title:Seminars in hematology

    pub_type: 历史文章,杂志文章

    doi:10.1053/j.seminhematol.2007.09.001

    authors: Gratwohl A

    更新日期:2007-10-01 00:00:00

  • The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS.

    abstract::The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry enrolls all consecutive patients for whom plasma exchange treatment is requested for clinically diagnosed TTP-HUS within a defined geographic region. During 14.5 years, from January 1, 1989 until June 30, 2003, 301 patients h...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1053/j.seminhematol.2003.10.001

    authors: George JN,Vesely SK,Terrell DR

    更新日期:2004-01-01 00:00:00

  • Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models.

    abstract::Acute promyelocytic leukemia (APL) is characterized by reciprocal chromosomal translocations that always Involve the retinoic acid receptor-alpha (RARalpha) gene on chromosome 17. RARalpha variably fuses to the PML, PLZF, NPM, NuMA, and STAT 5b genes (X genes), leading to the generation of X-RARalpha and RARalpha-X fu...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90006-x

    authors: Rego EM,Pandolfi PP

    更新日期:2001-01-01 00:00:00

  • Platelets in thrombotic disorders: quantitative and qualitative platelet disorders predisposing to arterial thrombosis.

    abstract::Endogenous thrombopoietin (TPO) stimulates platelet production in nonhuman primates by inducing dose-dependent megakaryocyte development from early marrow hematopoietic progenitors and subsequent proliferation and endoreduplication. In nonhuman primates, recombinant human TPO, nonpegylated or pegylated rHu megakaryocy...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Harker LA

    更新日期:1998-07-01 00:00:00

  • Anti-D treatment for pediatric immune thrombocytopenia: Is the bad reputation justified?

    abstract::The purpose of this study was to assess the efficacy and side effect profile of the repeated use of anti-D for the treatment of pediatric immune thrombocytopenia (ITP) in a large pediatric hematology center. We performed a retrospective analysis of patient records for children (aged 4 months-18 years) treated for ITP ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1053/j.seminhematol.2016.04.019

    authors: Yacobovich J,Abu-Ahmed S,Steinberg-Shemer O,Goldberg T,Cohen M,Tamary H

    更新日期:2016-04-01 00:00:00

  • Proteasome inhibition for antibody-mediated allograft rejection.

    abstract::Antibody-mediated rejection (AMR) is a major risk factor for graft loss following kidney transplantation. Traditional anti-humoral therapies provide suboptimal therapy and they do not deplete plasma cells, which are the source of antibody production. Proteasome inhibitors (PI) have been shown to deplete both transform...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2012.04.008

    authors: Sadaka B,Alloway RR,Shields AR,Schmidt NM,Woodle ES

    更新日期:2012-07-01 00:00:00

  • Bayesian interpretation and analysis of research results.

    abstract::From a computational perspective, Bayesian methods can be viewed as a natural extension of familiar confidence intervals and significance tests, which sheds light on their meaning. This viewpoint shows that no special software is required to compute Bayesian results, leaving the distinctions between conventional and B...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1053/j.seminhematol.2008.04.004

    authors: Greenland S

    更新日期:2008-07-01 00:00:00

  • Autologous hematopoietic cell transplantation for AML in first remission - An abandoned practice or promising approach?

    abstract::Patients with acute myeloid leukemia (AML) who achieve complete remission after induction therapy require post remission therapy (PRT) in order to remain disease free. The role of autologous hematopoietic cell transplantation (autoHCT) in the PRT setting is controversial and is largely based on older trials that were ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2019.01.001

    authors: Yeshurun M,Wolach O

    更新日期:2019-04-01 00:00:00

  • Immune dysregulation in immune thrombocytopenia.

    abstract::Immune thrombocytopenia (ITP) is a bleeding disorder characterized by low platelet counts due to decreased platelet production as well as increased platelet destruction by autoimmune mechanisms. A shift toward Th1 and possibly Th17 cells together with impaired regulatory compartment, including T-regulatory (Tregs) and...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2013.03.011

    authors: Yazdanbakhsh K,Zhong H,Bao W

    更新日期:2013-01-01 00:00:00

  • A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.

    abstract::This phase I trial of idarubicin (IDA) was conducted in 32 patients with acute leukemia and chronic myelogenous leukemia (CML) in blastic crisis (CML/BC) who either had failed to achieve a complete remission (CR) after initial induction therapy or had relapsed after CR. IDA was administered at dosages ranging from an ...

    journal_title:Seminars in hematology

    pub_type: 临床试验,杂志文章,评审

    doi:

    authors: Tamura K

    更新日期:1996-10-01 00:00:00

  • RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM).

    abstract::In this review, we discuss disease-causing alterations of RUNT-related transcription factor 1 (RUNX1), a master regulator of hematopoietic differentiation. Familial platelet disorder with predisposition to myeloid leukemia (FPDMM) typically presents with (1) mild to moderate thrombocytopenia with normal-sized platelet...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2017.04.006

    authors: Schlegelberger B,Heller PG

    更新日期:2017-04-01 00:00:00

  • Monitoring inhibitor patients with the right assays.

    abstract::The inhibitor titer is the most important clinical measurement in inhibitor patients, and the Nijmegen method is preferable to the original and well-established Bethesda assay for this purpose; however, both methods have high inter-laboratory variability. Monitoring inhibitor patients after treatment with bypassing ag...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2008.03.002

    authors: Barrowcliffe TW

    更新日期:2008-04-01 00:00:00

  • New anti-thrombotic agents: emphasis on hemorrhagic complications and their management.

    abstract::Our advanced knowledge of coagulation has led to the synthesis of novel procoagulant substances, such as recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark). Similarly, in-depth understanding of the interaction between anticoagulant proteins and their natural inhibitors has led to th...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.11.023

    authors: Ng HJ,Crowther MA

    更新日期:2006-01-01 00:00:00

  • Cobalamin deficiency in patients infected with the human immunodeficiency virus.

    abstract::Serum vitamin B12 levels are often low in human immunodeficiency virus (HIV)-infected patients. However, only a few patients appear to have actual vitamin B12 deficiency. A low red cell folate level accompanying the low vitamin B12 level makes the presence of vitamin B12 deficiency more likely. Our experience suggests...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Remacha AF,Cadafalch J

    更新日期:1999-01-01 00:00:00

  • Myelodysplastic syndrome in children and adolescents.

    abstract::Myelodysplastic syndromes (MDS) are clonal disorders characterized by ineffective hematopoiesis and subsequent frequent development of acute myeloid leukemia (AML). In children and adolescents, MDS are uncommon disorders, accounting for less than 5% of hematopoietic malignancy, with great heterogeneity in presentation...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1053/j.seminhematol.2007.10.006

    authors: Niemeyer CM,Baumann I

    更新日期:2008-01-01 00:00:00